A Multi-Center, Open-Label, Phase I Study of Single Agent RG7112: A First in Class p53-MDM2 Antagonist, in Patients with Relapsed/Refractory Acute Myeloid and Lymphoid Leukemias (AML/ALL) and Refractory Chronic Lymphocitic Leukemia/Small Cell Lymphocytic Lymphomas (CLL/SCLL)
Melanie Cree, professor at the University of Colorado Anschutz and lead author of the study, said the early findings suggest injectable semaglutide may help improve both areas simultaneously
Research has shown that these drugs have similar rates of cardiovascular mortality reduction, making them valuable options for managing cardiovascular risk in diabetic patients
Personalized Protocol Your Medical Director designs a PT 141 protocol based on your goals and health history
While the inflammation-reducing and fibrosis-attenuating effects of glucagon agonism are less well-characterized, the reductions in hepatic inflammation parameters and fibrosis observed in preclinical models likely reflect secondary effects consequent to improved steatosis, rather than direct anti-inflammatory actions [21]
During your consultation, your healthcare provider will assess several aspects of your health and wellness to determine if Ozempic treatment is right for you
